| Autor: |
Nkolika Nwankwo, Aswanth Reddy, Swarup Kumar, Maha Zafar |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Leukemia Research Reports, Vol 21, Iss , Pp 100459- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2213-0489 |
| DOI: |
10.1016/j.lrr.2024.100459 |
| Popis: |
Chronic Lymphocytic Leukemia (CLL) is the most common type of leukemia in the US, representing approximately 1.1% of all new cancers diagnosed. Most patients with CLL can be monitored without treatment, and the indicated treatment options include a CD20 monoclonal antibody with or without bruton tyrosine kinase (BTK) inhibitors, phosphatidylinositol 3-kinase (PI3K) inhibitors, and B-cell lymphoma 2 (BCL2) antagonists. We review the case of a 77-year-old female with a long-standing history of CLL predominant lymphocytosis, transfusion -independent anemia, and thrombocytopenia. Patient responded to zanubrutinib after initial failure of idelalisib, rituximab, and acalabrutinib and venetoclax. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
